Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1 Adverse events after typhoid fever vaccination reported to the Vaccine Adverse Events Reporting System, by vaccination date and vaccine type,

Published byRandell Waters Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 1 Adverse events after typhoid fever vaccination reported to the Vaccine Adverse Events Reporting System, by vaccination date and vaccine type,"— Presentation transcript:

1 Figure 1 Adverse events after typhoid fever vaccination reported to the Vaccine Adverse Events Reporting System, by vaccination date and vaccine type, United States, July 1990 through June 2002. From: Postmarketing Safety Surveillance for Typhoid Fever Vaccines from the Vaccine Adverse Event Reporting System, July 1990 through June 2002 Clin Infect Dis. 2004;38(6): doi: /381548 Clin Infect Dis | © 2004 by the Infectious Diseases Society of America

2 Table 1 Adverse events after typhoid fever vaccination reported to the Vaccine Adverse Event Reporting System by age, sex, severity, and vaccine type for currently licensed vaccines, United States, July 1990 through June 2002. From: Postmarketing Safety Surveillance for Typhoid Fever Vaccines from the Vaccine Adverse Event Reporting System, July 1990 through June 2002 Clin Infect Dis. 2004;38(6): doi: /381548 Clin Infect Dis | © 2004 by the Infectious Diseases Society of America

3 Table 2 Frequencies of the most common coadministered vaccines, by vaccine type, for adverse events after typhoid fever vaccination, United States, July 1990 through June 2002. From: Postmarketing Safety Surveillance for Typhoid Fever Vaccines from the Vaccine Adverse Event Reporting System, July 1990 through June 2002 Clin Infect Dis. 2004;38(6): doi: /381548 Clin Infect Dis | © 2004 by the Infectious Diseases Society of America

4 Table 3 Most common coding terms for adverse events reported after typhoid fever vaccination by vaccine type, United States, July 1990–June 2002. From: Postmarketing Safety Surveillance for Typhoid Fever Vaccines from the Vaccine Adverse Event Reporting System, July 1990 through June 2002 Clin Infect Dis. 2004;38(6): doi: /381548 Clin Infect Dis | © 2004 by the Infectious Diseases Society of America

5 Table 4 Serious adverse events reported to the Vaccine Adverse Event Reporting System after typhoid fever vaccination, United States, July 1990 through June 2002. From: Postmarketing Safety Surveillance for Typhoid Fever Vaccines from the Vaccine Adverse Event Reporting System, July 1990 through June 2002 Clin Infect Dis. 2004;38(6): doi: /381548 Clin Infect Dis | © 2004 by the Infectious Diseases Society of America

6 Table 5 Adverse events reported after Vi capsular polysaccharide vaccination assigned coding terms “laryngismus,” “edema tongue,” or “facial edema,” United States, July 1990 through June 2002. From: Postmarketing Safety Surveillance for Typhoid Fever Vaccines from the Vaccine Adverse Event Reporting System, July 1990 through June 2002 Clin Infect Dis. 2004;38(6): doi: /381548 Clin Infect Dis | © 2004 by the Infectious Diseases Society of America

Download ppt "Figure 1 Adverse events after typhoid fever vaccination reported to the Vaccine Adverse Events Reporting System, by vaccination date and vaccine type,"

Similar presentations

P449. p450 Figure 15-1 p451 Figure 15-2 p453 Figure 15-2a p453.

P449. p450 Figure 15-1 p451 Figure 15-2 p453 Figure 15-2a p453.
American Academy of Pediatrics, Committee on Infectious Diseases. Policy Updated Recommendations on the Use of Meningococcal Vaccines Pediatrics. doi:

American Academy of Pediatrics, Committee on Infectious Diseases. Policy Updated Recommendations on the Use of Meningococcal Vaccines Pediatrics. doi:
Figure 2 Power of likelihood ratio, log-rank, and Fisher’s exact tests as a function of the relative risk (RR) for different proportions of susceptible.

Figure 2 Power of likelihood ratio, log-rank, and Fisher’s exact tests as a function of the relative risk (RR) for different proportions of susceptible.
Figure 1 Overview of Markov model for infected total hip arthroplasty

Figure 1 Overview of Markov model for infected total hip arthroplasty
Table 4 Risk factors for acquisition of vancomycin-resistant enterococcal (VRE) colonization after transplantation for 120 liver transplant recipients.

Table 4 Risk factors for acquisition of vancomycin-resistant enterococcal (VRE) colonization after transplantation for 120 liver transplant recipients.
Table 5 Characteristics of 12 patients who had 1 test of stool samples that yielded positive results in the prospective clinical assessment for investigation.

Table 5 Characteristics of 12 patients who had 1 test of stool samples that yielded positive results in the prospective clinical assessment for investigation.
Table 3 Titers of antibody to hepatitis B surface antigen (anti-HBs) 2–4 weeks after the first vaccination From: Response to Hepatitis B Vaccine in HIV-1–Positive.

Table 3 Titers of antibody to hepatitis B surface antigen (anti-HBs) 2–4 weeks after the first vaccination From: Response to Hepatitis B Vaccine in HIV-1–Positive.
Table 1. Baseline Characteristics of the 36,636 Study Subjects

Table 1. Baseline Characteristics of the 36,636 Study Subjects
Figure 1. Varicella-related outpatient visit rates by age group, MarketScan 2003–2012. Varicella was the primary diagnosis code for data shown. Annual.

Figure 1. Varicella-related outpatient visit rates by age group, MarketScan 2003–2012. Varicella was the primary diagnosis code for data shown. Annual.
Figure 1. Disposition of study participants, by group. Data are no

Figure 1. Disposition of study participants, by group. Data are no
Table 6 The results of virus isolation tests before and after oseltamivir therapy. From: A Comparison of the Effectiveness of Oseltamivir for the Treatment.

Table 6 The results of virus isolation tests before and after oseltamivir therapy. From: A Comparison of the Effectiveness of Oseltamivir for the Treatment.
Table 4 Results of 3 pairwise comparisons of expanded virus groups, by use of least-squares means differences and the Tukey honestly significant difference.

Table 4 Results of 3 pairwise comparisons of expanded virus groups, by use of least-squares means differences and the Tukey honestly significant difference.
Table 1 Organisms for which rapid identification criteria are included. From: Rapid Identification of Bacteria and Yeast: Summary of a National Committee.

Table 1 Organisms for which rapid identification criteria are included. From: Rapid Identification of Bacteria and Yeast: Summary of a National Committee.
Table 1 Groups of subjects in a study of the association between antibiotic use and colonization with resistant pneumococci. From: Measuring and Interpreting.

Table 1 Groups of subjects in a study of the association between antibiotic use and colonization with resistant pneumococci. From: Measuring and Interpreting.
Table 1 Characteristics of patients at enrollment who received artesunate-amodiaquine (ASAQ) or artemether-lumefantrine (AL) for treatment of malaria.

Table 1 Characteristics of patients at enrollment who received artesunate-amodiaquine (ASAQ) or artemether-lumefantrine (AL) for treatment of malaria.
Table 3 Identification of Lactobacillus species isolated from blood cultures from Helsinki University Central Hospital, 1990–2000, and stored isolates.

Table 3 Identification of Lactobacillus species isolated from blood cultures from Helsinki University Central Hospital, 1990–2000, and stored isolates.
Table 1 Demographic and clinical characteristics of 758 admitted patients for whom cultures of nares were performed to assess methicillin-resistant Staphylococcus.

Table 1 Demographic and clinical characteristics of 758 admitted patients for whom cultures of nares were performed to assess methicillin-resistant Staphylococcus.
Table 1 Specificity of IgM immunoblot assay of sera collected during the winter and early spring months from volunteers without clinical evidence of Lyme.

Table 1 Specificity of IgM immunoblot assay of sera collected during the winter and early spring months from volunteers without clinical evidence of Lyme.
Table 1 Characteristics of study patients in survey of HIV infection in India. From: Natural History of Human Immunodeficiency Virus Disease in Southern.

Table 1 Characteristics of study patients in survey of HIV infection in India. From: Natural History of Human Immunodeficiency Virus Disease in Southern.
Table 3. Predictors of Nevirapine Reactions at Antiretroviral Therapy Initiation From: Strategies for Nevirapine Initiation in HIV-Infected Children Taking.

Table 3. Predictors of Nevirapine Reactions at Antiretroviral Therapy Initiation From: Strategies for Nevirapine Initiation in HIV-Infected Children Taking.

Similar presentations

Ads by Google